BCL6 and lymphoma: In the aggressive B-cell lymphoma subgroup (Table 2), HALs showed significantly higher CD10 positivity (51.16% vs. 21.05%; p = 0.003) and elevated BCL6 expression, with a median AOD of 0.35 (IQR, 0.22–0.43) compared to 0.205 (IQR, 0.00–0.32) in HIV-negative lymphomas (p = 0.003), as well as a larger positive area percentage for BCL6 (49.35% vs. 13.95%; p = 0.002).